Clinical Trial for Diabetes Medicine Shows Reduced Risk for CVD
Type 2 diabetics with CVD who were given the anti-diabetic sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin were observed to have a reduced risk of a heart failure or risk of death due to CVD. This observed in a trial follow-up of 3.1 years. The trial look partly positive as it is surely reducing the possibility of associated heart failure, a concern that has been rising one amongst diabetics. These patients were compared with a set of other patients who were given a placebo.
Date: Nov 17
More Indian Pharma Names Flock Japan’s Generic Markets
Since the previous Indian buyout in the Japanese Pharma sector that occurred over four years ago, there is a growth in the number of Indian Pharma firms that are looking for acquisition in Japan. Japan is currently ranked second in the largest drug markets in the world.
The second buyout made by Lupin Ltd., the Mumbai-based pharma company, was in 2011 in Japan. After that, none of the major Indian drug makers have been successful in creating a significant footprint in the Japan pharmaceutical m
Date: Nov 16
Teva Pharmaceutical Industries Ltd to Release Quarterly Dividend of US$0.34 on 3rd of December
Teva Pharmaceutical Industries has declared that it will release a quarterly dividend of $0.34 on the 3rd of December this year. Stockholders of record on the November 17th will receive thus dividend on the said date in December. On an annualised basis, the rate represents a $1.36 dividend and a yield of 2.26%. The company has declared that the ex-dividend date will be November 13th.
On Friday, Teva's shares opened at 60.19 (NASDAQ:TEVA). The company has a market value of US$51.28 billion a
Date: Nov 06
Vitamin D Supplements Can Improve an Individual’s Exercise Performance
Consuming vitamin D supplements can enhance exercise performance and reduce the risk of cardiac diseases, says a new study.
Vitamin D, which is both a hormone and a vitamin, helps to control levels of phosphate and calcium present in the blood. It is also essential for teeth and bone strength.
Co-author of the study, Raquel Revuelta Iniesta, hailing from the Queen Margaret University of Edinburgh said that their study indicates consuming Vitamin D supplements can help boost the fitness lev
Date: Nov 03
Teva Pharmaceutical Third Quarter Profit Surpass Estimates, Company Raises 2015 Outlook
Teva Pharmaceuticals, the world’s largest manufacturer of generic drugs, has reported profits in the third financial quarter of the year that have beaten estimates. The company has thus raised its forecast for the entire financial year.
Teva Pharmaceuticals, which is currently in the process of buying the generic medicines wing of the Ireland-based pharmaceutical company Allergen for US$40.5 billion and the Mexican company Rimsa for US$2.3 billion, stated on Thursday that the company had earn
Date: Nov 02
India Gets is First Ayurvedic Remedy for Diabetes
xCouncil of Scientific and Industrial Research (CSIR) lab in Lucknow, India launched its Ayurvedic drug that has been validated to for Type 2 Diabetes. The drug is called BGR-34 and has been co-developed by Central Institute for Medicinal and Aromatic Plant (CIMAP) and National Botanical Research Institute (NBRI). Both these units have been funded by the government. This drug will be manufactured by Aimil Pharmaceuticals in New Delhi.
In an interesting announcement a CSIR official stated that t
Date: Oct 27
China and the U.K. Sign Healthcare Deals of GBP 2bn
Healthcare deals and colorations that are more than GBP 2 bn have been signed between British and Chinese companies, organizations, and universities in a recent visit of Chinese President Xi Jinping to Britain.
Addressing at the Life Science and Healthcare Business Forum, the minister for Life Science stated that the collaborations are slated to provide a benefit that would go beyond the British and Chines populations. The recently signed deals and collaborations will positively affect the glob
Date: Oct 23
Strong Buy Rating Given to Bio Blast by Brokerages
A consensus rating of 1.0 has been allotted to Bio Blast Pharma by brokers, indicating a strong buy rating. The rating was given by the brokers which offer coverage for the company’s stocks. There were two investment analysts that rate the stock with a strong buy suggestion.
A 1-year long consensus cost objective has been allotted by brokerages, amounting to US$28.50 for Bio Blast Pharma. They have also forecasted that the firm will submit a US$0.29 EPS for this quarter. Zacks Investment Rese
Date: Oct 19
Valeant Pharmaceuticals Receives Subpoena Regarding Unprecedented Price Hike of Popular Drugs
Valeant Pharmaceuticals, the global pharmacy giant renowned for its extensive drug portfolio of branded, generic, over-the-counter drugs, and medical devices, has recently been under the scrutiny related to practices considered price gouging. Following the comment of Democratic Presidential candidate Hilary Clinton about the rising prices of specialty medicines, which brought turmoil in the overall biotech sector, Valeant’s shares also observed a steep decline in the month of September.
Date: Oct 16
Democratic Debate in the U.S. Focuses on Healthcare Insurance for Illegal Immigrants
The Democratic debate has made it clear that the two candidates of the party for presidential nomination would allow illegal immigrants in the U.S. to buy medical coverage from government websites, but to only a limited range.
The healthcare overhaul of 2010, which was supported by all the presidential candidates on the stage in a debate held on Tuesday night, requires that immigrants prove their legal residency to be eligible to buy medical coverage from HealthCare.gov or obtain tax credits fo
Date: Oct 14